# Pamicell signs supply contract with Thermo Fisher Scientific for pharmaceutical intermediates

Pamicell announced it signed a supply contract for pharmaceutical intermediate nucleosides with Thermo Fisher Scientific, worth 1.86 billion KRW.

- Type: Contract
- Announced: 2020-02-19
- Where: South Korea
- Value: $1.55M (1.86B KRW)
- Status: announced
- Products: pharmaceutical intermediate nucleosides
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Pamicell](https://endata.com/companies/45375.md)
- [Thermo Fisher Scientific](https://endata.com/companies/7061.md) (customer)

## Sources

- [asiae.co.kr](https://www.asiae.co.kr/en/article/2020021910012463269), 2020-02-19: "Pamisel, a stem cell therapy research and development company, announced on the 19th that it has signed a supply contract for pharmaceutical intermediate nucleosides with Thermo Fisher Scientific."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.